{"nctId":"NCT00885079","briefTitle":"Confirmatory Study of OPC-12759 Ophthalmic Suspension","startDateStruct":{"date":"2009-05"},"conditions":["Dry Eye Syndromes"],"count":188,"armGroups":[{"label":"Rebamipide","type":"EXPERIMENTAL","interventionNames":["Drug: OPC-12759 Ophthalmic suspension"]},{"label":"Hyaluronate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Hyalein Mini Ophthalmic solution"]}],"interventions":[{"name":"OPC-12759 Ophthalmic suspension","otherNames":[]},{"name":"Hyalein Mini Ophthalmic solution","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Out patient\n2. Subjective complaint of dry eye that has been present for minimum 20 months\n3. Ocular discomfort severity is moderate to severe\n4. Corneal - conjunctival damage is moderate to severe\n5. Unanesthetized Schirmer's test score of 5mm/5minutes or less\n6. Best corrected visual acuity of 0.2 or better in both eyes\n\nExclusion Criteria:\n\n1. Presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis sicca\n2. Ocular hypertension patient or glaucoma patient with ophthalmic solution\n3. Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study\n4. Anticipated use of contact lens during the study\n5. Patient with punctal plug\n6. Any history of ocular surgery within 12 months\n7. Female patients who are pregnant,possibly pregnant or breast feeding\n8. Known hypersensitivity to any component of the study drug or procedural medications\n9. Receipt of any investigational product within 4 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Fluorescein Corneal Staining (FCS) Score From Baseline","description":"FCS indicates the damage to the corneal epithelium. Per the National Eye Institute/Industry Workshop report, the cornea was divided into 5 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-15). 0 is better. Noninferiority for change from baseline in the FCS score (LOCF) was determined by comparing the noninferiority margin (0.4) with the upper limit of the 95% confidence interval (CI) of the difference between the 2 treatment groups","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"0.3"},{"groupId":"OG001","value":"-2.9","spread":"0.2"}]}]}]},{"type":"PRIMARY","title":"Change in Lissamine Green Conjunctival Staining (LGCS) Score From Baseline","description":"LGCS indicates the damage to the conjunctival epithelium. Per the National Eye Institute/Industry Workshop report, the conjunctiva was divided into 6 fractions, each of which was given a staining sdore from 0 to 3, and the total score was calculated (0-18). 0 is better. Superiority was verified by comparing t-test results for change from baseline in the LGCS score (LOCF) between 2 treatment groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","spread":"3.2"},{"groupId":"OG001","value":"-2.4","spread":"2.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":93},"commonTop":["Dysgeusia (bitter taste)","Eye pruritus","Conjunctival haemorrhage","Eye pain","Nasopharyngitis"]}}}